PRME

Prime Medicine Stock Analysis

AI Rating

Neutral
  • Quality1/10
  • Growth↑ 6/10
  • Momentum↑ 7/10
Prime Medicine sales and earnings growth
PRME Growth
Good
  • Revenue Y/Y↑ 647.13%
  • EPS Y/Y↑ 30.10%
  • FCF Y/Y↑ 39.52%
Prime Medicine gross and profit margin trends
PRME Profitability
Neutral
  • Gross margin ↑ 100.00%
  • EPS margin↓ -3301.60%
  • ROIC↓ -72.20%
Prime Medicine net debt vs free cash flow
PRME Risk
Great
  • Debt / Equity↓ 0.7
  • Debt / FCF↓ 0.3
  • Interest coverage↓ NA

Prime Medicine stock volatility is higher than the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗